Lantern Pharma FDA Clears Pediatric Trial Lantern Pharma won FDA clearance on Mar 27, 2026 to start a Phase 1 pediatric DIPG trial; DIPG carries median survival under 12 months and ~200–400 US cases/year.

Lantern Pharma FDA Clears Pediatric Trial: Lantern Pharma won FDA clearance on Mar 27, 2026 to start a Phase 1 pediatric DIPG trial; DIPG carries median survival under 12 months and ~200–400 US cases/year. 👈 Read full analysis #LanternPharma #FDAClearance #PediatricTrial #DIPG #ClinicalResearch